参考文献/References:
[1] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[2] Zheng S,Bai JQ,Li J,et al.The pathologic characteristics of breast cancer in China and its shift during 1999-2008:A national-wide multicenter cross-sectional image over 10 years[J].Int J Cancer,2012,131(11):2622-2631.
[3] Mary CS,Charles FL,Taher AH,et al.Chemotherapy use and surgical treatment by receptor subtype in node-negative t1a and t1b female breast cancers,iowa SEER registry,2010- to 2012[J].Clinical Breast Cancer,2015,15(1):27-34.
[4] Gamucci T,Vaccaro A,Ciancola F,et al.Recurrence risk in small,node-negative,early breast cancer:A multicenter retrospective analysiss[J].J Cancer Res Clin Oncol,2013,139(5):853-860.
[5] Crochet P,Molinari N,Darmon JC,et al.Follow-up of patients treated for pT1aN0M0breast cancer:10-year survival and prognostic factors[J].Breast Journal,2016,22(3):363-365.
[6] 杨国荣,周 宇,奚天益,等.21基因复发风险评分与乳腺癌临床病理因素的相关性[J].中国现代普通外科进展,2021,24(9):684-688.
[7] 刘玲玲,林 芳,韩耀风,等.不同分子分型乳腺癌术后复发转移风险及其时间分布规律[J].中国卫生统计,2017,34(1):7-14.
[8] Foo CS,Su D,Chong CK,et al.Breast cancer in young Asian women:Study on survival[J].Anz Journal of Surgery,2015,75(7):566-572.
[9] Regan MM,Francis PA,Pagani O,et al.Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive,human epidermal growth factor receptor 2-negative early breast cancer:TEXT and SOFT trials[J].J Clin Oncol,2016,34(19):2221-2231.
[10] Regan MM,Francis PA,Pagani O,et al.Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapy for premenopausal women with HR+HER2-negative breast cancer:Results from TEXT and SOFT[J].J Clin Oncol,2018,36(15):503-503.
[11] Lee JY,Lim SH,Lee MY,et al.Impact on survival of regular postoperative surveillance for patients with early breast cancer[J].Cancer Research & Treatment Official Journal of Korean Cancer Association,2015,47(4):639-639.
[12] 欧开萍,罗 扬,吕剑虹,等.HER2阳性早期乳腺癌患者的预后分析[J].癌症进展,2019(16):1935-1938.
[13] 尹树山,陶 艳,张红英.雌、孕激素受体在晚期局部乳腺癌中的表达及与患者预后相关性研究[J].陕西医学杂志,2019,48(12):1718-1721.
[14] Cameron D,Piccart-Gebhart MJ,Gelber RD,et al.11 years follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer:Final analysis of the HER ceptin adjuvant(HERA)trial[J].Lancet,2017,389(10075):1195-1205.
[15] 马少君,刘延梅,张月浪,等.原发性乳腺癌HER2过表达与钼靶影像学及临床特征相关性研究[J].陕西医学杂志,2017,46(3):307-309.
[16] Petrelli F,Barni S.Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0breast cancer:A systematic review of the literature with a pooled-analysis[J].Medical Oncology,2012,29(4):2586-2593.
[17] O'Sullivan CC,Bradbury I,Campbell C,et al.Efficacy of Adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm:A meta-analysis of the randomized trastuzumab trials[J].J Clin Oncol,2015,33(24):2600-2608.
[18] Brollo J,Curigliano G,Disalvatore D,et al.Adjuvant trastuzumab in elderly with HER-2 positive breast cancer:A systematic review of randomized controlled trials[J].Cancer Treatment Reviews,2013,39(1):44-50.
[19] Perez EA,Romond EH,Suman VJ,et al.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer:Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J].J Clin Oncol,2014,32(33):3744-3752.
[20] Slamon DJ,Eiermann W,Robert NJ,et al.Abstract S5-04:Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel(AC→T)with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab(AC→TH)with docetaxel,carboplatin and trastuzumab(TCH)in HER2+ early breast cancer[J].Cancer Research,2016,76(4):1112-1123.
[21] 崔世恩,储 兵,凌飞海.390例原发乳腺癌远处转移与分子分型关联性的10年回顾性分析[J].中国癌症杂志,2015,25(10):774-779.
[22] 刘 丹,胥 旸,邢晓静.鸦胆子苦醇对三阴性乳腺癌细胞凋亡的影响[J].陕西中医,2021,42(4):419-422.
[23] 陈玮黎,薛晓红,李思雨,等.扶正祛邪方对三阴性乳腺癌术后复发转移及免疫功能的影响[J].陕西中医,2021,42(6):739-742.
相似文献/References:
[1]冯瑞,刘颖丽,王平侠,等.个体化心理干预对乳腺癌患者负性情绪和生活质量的影响[J].陕西医学杂志,2016,(10):1441.
[2]安改丽,侯磊,李旭,等.miR-145对人乳腺癌MCF-7/ADR细胞耐药逆转的作用机制研究[J].陕西医学杂志,2017,(06):695.
[3]张阳,赵巧玲,夏晓娜,等.超声弹性应变率比值对乳腺癌腋窝淋巴结转移的鉴别诊断价值[J].陕西医学杂志,2017,(06):709.
[4]郭 丹.钬激光碎石术治疗上段输尿管结石效果及复发危险因素分析[J].陕西医学杂志,2020,49(5):575.
[5]尹 梅.喘息性支气管炎患儿红细胞分布宽度与其预后相关性研究[J].陕西医学杂志,2020,49(7):841.[doi:DOI:10.3969/j.issn.10007377.2020.07.020]
YIN Mei..Correlation between red cell distribution width and prognosis in children with asthmatic bronchitis[J].,2020,49(11):841.[doi:DOI:10.3969/j.issn.10007377.2020.07.020]
[6]刘 坤.鼻内翻性乳头状瘤术后复发影响因素分析*[J].陕西医学杂志,2020,49(10):1256.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.014]
[7]余 伟,雷 斌.区域型肝内胆管结石手术方法选择及术后结石残留、复发的危险因素分析[J].陕西医学杂志,2021,50(1):36.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.009]
YU Wei,LEI Bin.Selection of surgical methods for regional intrahepatic bile duct stones and analysis of risk factors for postoperative stone residual and recurrence[J].,2021,50(11):36.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.009]
[8]何海涛,王智翔,张小弟,等.趋化因子配体13在肝细胞癌组织中的表达及与临床病理特征和预后关系[J].陕西医学杂志,2021,50(2):236.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.028]
HE Haitao,WANG Zhixiang,ZHANG Xiaodi,et al.Expression of CXCL13 in hepatocellular carcinoma and its correlation with clinicopathological features and prognosis[J].,2021,50(11):236.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.028]
[9]方锋助,牒 军,李展奇,等.经皮椎间孔镜椎间盘切除术治疗腰椎间盘突出症复发情况及影响因素分析[J].陕西医学杂志,2021,50(3):297.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.010]
[10]原 宁,宁 萍.微生态制剂联合奥美拉唑序贯治疗幽门螺旋杆菌阳性消化性溃疡效果及对患儿丙二醛、转化生长因子β1蛋白水平和肠道菌群的影响[J].陕西医学杂志,2021,50(4):472.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.023]
YUAN Ning,NING Ping.Effect of probiotics combined with omeprazole sequential therapy in treatment of Helicobacter pylori-positive peptic ulcer and its influence on MDA,TGF-β1 protein levels and intestinal flora in children[J].,2021,50(11):472.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.023]